Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18138425 | 0.88 | TDP1 (0.45) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL5964869 | 0.87 | KDM4E (0.44) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL5964706 | 0.87 | TDP1 (0.44) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL11748681 | 0.87 | KDM4E (0.44) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL1882600 | 0.87 | TDP1 (0.47) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL8950197 | 0.87 | KDM4E (0.47) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL16033385 | 0.84 | ALDH1A1 (0.42) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL28527757 | 0.84 | ALDH1A1 (0.42) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL5373510 | 0.84 | KDM4E (0.45) | TDP1KDM4EPOLBL3MBTL1CTDSP1 | |
| SCHEMBL14494983 | 0.84 | POLB (0.45) | TDP1KDM4EPOLBL3MBTL1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264612-A1 | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA | UNIV COLUMBIA (US) | 2016-09-15 | — | — | US | claimed |
| US-20130096015-A1 | Massive Parallel Method For Decoding DNA And RNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-04-18 | — | — | US | claimed |
| US-7345159-B2 | Massive parallel method for decoding DNA and RNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-03-18 | — | — | US | claimed |
| EP-1790736-A2 | Massive parallel method for decoding DNA and RNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-05-30 | — | — | EP | claimed |
| EP-1337541-B1 | Massive parallel method for decoding DNA and RNA | UNIV COLUMBIA (US) | 2007-03-07 | — | — | EP | claimed |
| US-20040185466-A1 | to detect single nucleotide polymorphisms, genetic mutation, gene expression, forensic identification, disease association, DNA/genomic sequencing and translation/transcription analysis; solid phase synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. | 2004-09-23 | — | — | US | claimed |
| EP-1337541-A4 | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA | UNIV COLUMBIA (US) | 2004-07-14 | — | — | EP | claimed |
| JP-2004510433-A | — | — | 2004-04-08 | — | — | JP | claimed |
| US-6664079-B2 | Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2003-12-16 | — | — | US | claimed |
| EP-1337541-A2 | Massive parallel method for decoding DNA and RNA | The Trustees of Columbia University in the City of New York (US) | 2003-08-27 | — | — | EP | claimed |
| US-20020102586-A1 | Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences | NATIONAL SCIENCE FOUNDATION | 2002-08-01 | — | — | US | claimed |
| WO-2002029003-A2 | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2002-04-11 | — | — | WO | claimed |
| US-11940413-B2 | Methods and devices for sequencing nucleic acids in smaller batches | IsoPlexis Corporation (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN SCIENCES, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2023-12-21 | — | — | US | disclosed |
| US-6664079-B2 | Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2003-12-16 | — | — | US | disclosed |
| EP-1337541-A2 | Massive parallel method for decoding DNA and RNA | The Trustees of Columbia University in the City of New York (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020102586-A1 | Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences | NATIONAL SCIENCE FOUNDATION | 2002-08-01 | — | — | US | disclosed |
| WO-2002029003-A2 | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264612-A1 | MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA | RNGTT, NSUN2, RNMT | TDP1 299/4885KDM4E 909/4885POLB 25/4885 |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | TDP1 116/4885KDM4E 4166/4885POLB 44/4885 |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | TDP1 116/4885KDM4E 4166/4885POLB 44/4885 |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | TDP1 116/4885KDM4E 4166/4885POLB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.